This web uses cookies in order to offer the best user experience. Cookies information is stored in your browser and performs functions such as recognising you when you come back to our website or helping our team to understand which sections of our website are more interesting and useful to you.
About us
ALA Diagnostics aims to be a developer and marketer of In Vitro Diagnostic Kits for pathologies with high prevalence and/or unresolved medical needs, based on existing synergies with some of the Public Bodies with the greatest capacity to generate innovative projects.
ALA Diagnostics was created as a result of the identification of an opportunity for the development of a blood diagnostic kit for Multiple Sclerosis, based on a patented recombinant protein whose activity as a diagnostic biomarker has already been clinically validated in more than 500 people: ALA Diagnostics EM KIT.
Diagnosis is an indispensable tool in maintaining the health of the population, as it identifies the problem and is therefore the first step towards solving it. In vitro diagnostic tests provide information on the health of patients through the analysis of samples, the distinguishing feature of which is that they are never in direct contact with the patient.
Products
The ALA Diagnostics Pipeline is based on products designed by clinical teams to address the gaps they encounter in their care activities.
They are designed to be easily integrated into the clinical routine and have a clinical development plan, a large network of patients for clinical validation and close interaction with health and regulatory authorities, which are vital to the success of the project.
Multiple Sclerosis:
- Ala diagnostics EM kit: Fast Market Access. Low Regulatory Risk. High Acceptance by Clinicians and Patients.
- Diagnostic Algorithm: Increases Diagnostic Robustness. Includes all Available Diagnostic Tools
- Selection of Treatment: It allows the Best Treatment to be selected for each patient. By means of Artificial Intelligence, It can Predict the Prognosis.
- Biomarker Response: Of Great Value to Big Pharma Developing and Marketing Alternatives to interferon Beta.
Other Lines Under Evaluation:
- Diagnosis of Antibiotic Allergy
- Oncological Diagnosis
In Experimental Development Phase, In Contact with the OPIS
Diagnosis is an indispensable tool in maintaining the health of the population.
In vitro diagnostic tests, in addition to confirming or ruling out the presence of a pathology, guide medical specialists in the selection of the most appropriate therapy for each patient, facilitating personalised medicine. In vitro diagnostic tests help to reduce the incidence of certain pathologies or the length of hospital stays, as well as to increase the health of the population in general.
In vitro diagnostic tests contribute to the cost reduction of national healthcare systems and to the economic growth of society.
The global in vitro diagnostics market in 2017 amounted to USD 52 billion and is growing at an annual rate of 4.2%. Most of the market is concentrated in a few multinationals.
In Spain, 70% of clinical decisions today depend on in vitro diagnostic tests. In vitro diagnostic tests are requested in 1 out of every 11 primary care consultations, in 1 out of every 2 emergencies, in 1 out of every 2 specialised consultations.
In Spain alone in 2015, according to Ministry of Health estimates, 60 million laboratory requests and more than 604 million tests were performed.
Team
José Ramón Montero
CEO
Pharmacist. He has 14 years of experience in the biotechnology sector, performing functions related to R&D&I project management, project viability analysis, business plan development, business strategy and advising biotech start-ups.
Dr. Óscar Fernández
CSO
Clinical neurologist with more than 40 years of experience. A reference in the clinical diagnosis of Multiple Sclerosis. He has participated in more than 100 clinical trials related to Multiple Sclerosis. He is the inventor of the patents. He has published more than 200 articles in indexed journals.
Dr. José Pavía
CSO R&D
Doctor of Medicine. Full professor and scientist at the Faculty of Medicine of the University of Malaga, in the area of Pharmacology. He has more than 30 years of research experience. He is the inventor of the patents. He has published more than 70 publications.
Virginia Moreno
Marketing
Pharmacist. She has 15 years of experience in multinationals in the pharmaceutical sector. She has led the launch of products in the pharmacy, parapharmacy and consumer channels.
Itziar Ochotorena
R&D Teams
She has 16 years of experience in senior management positions in leadership and management of private and public biomedical research organisations.
Laura Obiols
Regulatory Affairs
She has worked as a research director at the European Commission, has collaborated with the WHO and as a specialist at the Royal Pharmaceutical Society.
Innovative Bioconsulting
R&D Projects
Strategic consultancy specialising in the biotechnology sector.
Gustavo Fuster
Advisor
European Patent Attorney with CEIPI Diploma in European Patent Litigation.
Contact
Where to find us
López de Hoyos, 27
28006 Madrid – Spain
Join our project
ALA Diagnostics has launched a funding round to complete the development of the first test for the early diagnosis of Multiple Sclerosis in blood.
This product will revolutionise the diagnosis of MS by allowing an early, simple, fast, cheap and reliable diagnosis in a non-invasive way, as it only requires a blood test to carry it out.
Our diagnostic kit is based on a patented recombinant protein that has been clinically validated in 598 human samples through clinical studies with patients.
We have the only clinically validated biomarker for the diagnosis of MS in blood. There is no other on the market. It is a test that can be easily integrated into the clinical routine and is supported by clinicians, patient organisations and healthcare systems.
Our diagnostic kit reduces costs and the time needed to detect the disease and helps eliminate misdiagnosis, which facilitates diagnosis and allows treatments to be initiated at the earliest stages of the disease, improving its efficacy and therefore the quality of life of patients.
It is a universal test that, because of its simplicity and low cost, can be used to diagnose MS in any country in the world and help MS sufferers anywhere in the world, without the need for complex equipment or large investments.